ClinicalTrials.gg
RecruitingNCT06176508Updated Jul 18, 2024

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

A Phase 2 interventional study of HS-10374 and HS-10374-matched placebo tablets in Psoriatic Arthritis, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic with a site in China — 10 open to participants now, 19 under way, 11 of them phase 3. Arthritis, Psoriatic · China.

Planned enrollment
18th of 27
160 · median 208
Started
2024
with 3 others
Phase 2
5 of 34
3 open now
Primary completion
2026-04
later than 4 of 18 live
Registered
19th of 34
by date

Among the 34 studies in Arthritis, Psoriatic with a site in China, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 2, reaches primary completion later than 4 of the 18 other live ones, and was the 19th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 34 studies in Arthritis, Psoriatic with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic with a site in China, or all of them as a file.
02

Study summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 18-75 years.
  2. Has a history of psoriatic arthritis (PsA) for at least 6 months, and meets the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening.
  3. Active arthritis as shown ≥ 3 swollen joints (66 joints) and ≥ 3 tender joints (68 joints) at both screening and baseline.
  4. Active plague psoriatic skin lesion or documented history of plague psoriatic at screening.
  5. hs-CRP ≥ 3mg/L at screening.
  6. Subjects either (i) do not have prior exposure to biologics (biologic-naïve) or (ii) have failed or been intolerant to 1 TNF-inhibitor (TNFi-experienced).

Exclusion criteria

Exclusion Criteria:

  1. Non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis), with the exception of nail psoriasis, which is allowed.
  2. Other or autoinflammatory condition ( ie, rheumatoid arthritis, systemic lupus erythematous, gout), with the exception of inflammatory bowel disease and/or autoimmune uveitis being inactive at least 12 months before the screening, as assessed by the investigator.
  3. Active fibromyalgia syndrome
  4. Recent history of active infection, chronic infection history or risk of serious infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    HS-10374 Dose 1

    Drug: HS-10374

  • Experimental
    HS-10374 Dose 2

    Drug: HS-10374

  • Placebo comparator
    Placebo

    Drug: HS-10374-matched placebo tablets

  • Active comparator
    tofacitinib

    Drug: Tofacitinib 5Mg Tab,Oral

Interventions

  • Administered orally QD for 16 weeks

  • DrugHS-10374-matched placebo tablets

    Administered orally QD for 16 weeks

  • Administered orally BID for 16 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Time frame: At week 16

Secondary outcomes

  1. Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 12

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Time frame: At week 12

  2. Proportion of participants meeting American College of Rheumatology improvement of 50% (ACR50) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Time frame: At week 16

  3. Proportion of participants meeting American College of Rheumatology improvement of 70% (ACR70) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Time frame: At week 16

  4. Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 16

    The HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a subject has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For reach item in the questionnaire the level of activity is cored from 0 to 3 with 0 representing "no difficulty", 1 as "some difficulty", 2 as much "difficulty", and 3 has "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a score of 2 or more.

    Time frame: At week 16

  5. Proportion of participants meeting Psoriasis Area and Severity Index (PASI) 75/90 responses at week 16

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75, PASI 90 responses are defined as 75% or 90% improvement in PASI score from baseline.

    Time frame: At week 16

  6. Proportion of participants meeting Static physician's global assessment (sPGA) 0/1 score at week 16

    Static physician's global assessment (sPGA) of psoriasis is an average assessment of all psoriatic lesions based on erythema, induration, and scale. It's a 5-point scale performed by investigators. A sPGA score of 0 or 1 means "clear" or "almost clear" respectively.

    Time frame: At week 16

  7. Change from baseline in Psoriasis body surface area (BSA) at week 16

    Psoriasis body surface area (BSA) involvement is measured using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.

    Time frame: At week 16

  8. Change from baseline in the dermatology life quality index (DLQI) scores at week 16

    The dermatology life quality index (DLQI) is a patient reported outcome measurement. It's a questionnaire consisting of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. Each question is scored on a scale of 0 to 3, and the sum of each scores range from 0 (no impairment of life quality) to 30 (maximum impairment).

    Time frame: At week 16

  9. Change from baseline in Disease Activity Score 28 with C-reactive protein (DAS28-CRP) score at week 16

    DAS28-CRP is a composite outcome measure that assesses: Numbers of joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, except for distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28; Hypersensitive-CRP in the blood to measure the degree of inflammation; Subject Global Assessment of disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: ≤2.6: Disease remission; 2.6 - 3.2: Low disease activity; 3.2 - 5.1: Moderate disease activity; \>5.1: High disease activity.

    Time frame: At week 16

  10. Change from baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA) at week 16

    The Disease Activity Index for Psoriatic Arthritis Score (DAPSA) is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count, swollen joint count, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and hs-CRP.

    Time frame: At week 16

  11. Proportion of participants meeting Minimal Disease Activity (MDA) response at week 16

    Minimal Disease Activity (MDA) response is defined as a subject fulfilling 5 of 7 of the following outcomes: tender joint count ≤ 1; swollen joint count ≤ 1; PASI ≤ 1 or body surface area (BSA) ≤ 3%; Subject Global Assessment of pain ≤ 15; Subject Global Assessment of disease activity ≤ 20; HAQ-DI ≤ 0.5; Tender entheseal points ≤ 1

    Time frame: At week 16

  12. Change from baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at week 16

    A composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the LEI, the tendor dactylitis count and the hs-CRP.

    Time frame: At week 16

  13. Proportion of participants achieving Psoriatic Arthritis Response Criteria (PsARC) at week 16

    The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of psoriatic arthritis. In order to be classified as a PsARC responder, subjects must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.

    Time frame: At week 16

  14. Change from baseline in the Short Form-36 Survey (SF-36) score at week 16

    The SF-36 is a patient-reported outcome measure in clinical practice and research. The instrument includes 36 items to measure the following 8 health dimensions over the past 4 week: 1) limitations in physical activities, such as bathing or dressing; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality; and 8) general health perceptions.

    Time frame: At week 16

  15. Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score among participants with spondylitis as one of their presentations of PsA at week 16

    Symptoms of spondylitis over the past week will be evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: * Fatigue * Spinal pain * Joint pain and swelling * Areas of localized tenderness * Morning stiffness duration * Morning stiffness severity A higher count indicates worse disease.

    Time frame: At week 16

  16. Change from baseline in dactylitis by Leed's dactylitis index (LDI) at week 16

    Leed's Dactylitis Index (LDI) is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. A higher score indicates worse dactylitis and is based on the current evaluation.

    Time frame: At week 16

  17. Change from baseline in enthesitis by Leed's enthesitis index (LEI) at week 16

    The Leed's enthesitis index (LEI) was developed specifically for PsA. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Time frame: At week 16

  18. Incidence of adverse events (AEs), serious adverse events (SAEs)

    Time frame: Baseline to Week 20

  19. Ctrough of HS-10374

    Trough observed plasma concentration of HS-10374

    Time frame: Baseline to Week 16

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Apr 2026, 26 months after the start.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 19, 2023
StartActual
Feb 26, 2024
Primary completionEst.
Apr 28, 2026
CompletionEst.
Aug 28, 2026
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06176508
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Feb 26, 2024
Primary completion
Apr 28, 2026 (estimated)
Completion
Aug 28, 2026 (estimated)
Last update
Jul 18, 2024

Study contacts

Hejian Zou, PhD
Contact
hjzou@unirheuma.org
+86-13311881366
Hejian Zou, PhD
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10374

Start the discussion